Experimental cataract lens can treat glaucoma through time-release drugs

A new clinical trial has shown that an experimental cataract lens, which also contains a glaucoma medication, can effectively treat both cataracts and glaucoma in patients. The artificial lens releases a drug called bimatoprost gradually into the eye over time. After one year, patients who received the experimental lens had similar eye pressure levels to those who had a standard cataract lens and took twice-daily eyedrops for glaucoma.

Nearly all of the patients who received the drug-releasing lens did not require any additional glaucoma medications.

The lead researcher, Dr. Jeffrey Kammer, highlighted the unique aspect of this treatment, stating that it is the first of its kind to address both cataracts and glaucoma simultaneously. Glaucoma, which damages the optic nerve due to increased eye pressure, is a common cause of blindness, often managed with daily eyedrops. However, adhering to this treatment regimen can be challenging, especially for older patients.

Cataracts, which cause clouding of the eye's natural lens, are also a prevalent condition, frequently treated with surgery and replacement lenses.

The researchers' idea of infusing artificial lenses with glaucoma medication was promising, given the high prevalence of both conditions among aging individuals. For the trial, 106 patients with glaucoma or high eye pressure, scheduled for cataract surgery, were randomly assigned to receive either the experimental lenses or a standard replacement lens followed by timed glaucoma drops.

After a year, the drug-releasing lens group had eye pressure levels comparable to the timed eyedrop group, with over 95% of patients needing no additional medication. The trial will continue for three years to assess the treatment's long-term durability and safety.